Score Breakdown
Trash.
Absci is a high-risk, pre-revenue clinical-stage biotech trading at a $917M market cap with negligible revenue, ~$100M+ annual cash burn, 23% annual dilution, and 26% short interest. The company has already pivoted its lead program once (from ABS-101 to ABS-201), signaling competitive weakness, and now faces binary clinical risk on an early-stage prolactin receptor antagonist in a crowded market. The AI platform narrative has not translated into commercial partnerships or meaningful revenue, and management has failed to deliver on prior guidance (major pharma deal by end of 2025). With cash declining rapidly, further dilutive raises are inevitable. At current valuation, the market is pricing in significant clinical and commercial success that is years away and highly uncertain. The risk/reward is skewed negatively for equity holders given the dilution trajectory, competitive landscape (HMI-115 is ahead), and management credibility concerns.
Negative cash flow. Can't value it.
Some yellow flags.
Shares melting fast.
Neutral.
Tight but ok.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The bear case centers on Absci's status as a 'story stock' with deteriorating fundamentals. Despite the AI hype, the company is effectively pre-revenue with a massive negative net margin exceeding 4,000%. Short interest remains elevated at approximately 25.6% of the float as of April 2026, indicating high conviction among skeptics that the current valuation is unsustainable. The 'lab-in-the-loop' platform has yet to translate into meaningful milestone payments or high-value contracts, and the deprioritization of ABS-101 suggests the company is struggling to compete with deep-pocketed pharma giants (Zacks, Benzinga).
🔍 What's In The SEC Filings
The company is facing a rapid cash burn with negligible revenue and is sustaining operations through aggressive equity dilution and creative accounting of partner premiums.
Extreme Revenue Concentration Risk
“During the three months ended March 31, 2026, two partners represented 100% of total partner program revenue.”
The company's entire revenue stream is dependent on only two entities, making it highly vulnerable to contract terminations or disputes.
Aggressive At-The-Market (ATM) Dilution
“During the three months ended March 31, 2026, the Company issued and sold 2,871,218 shares and received $8.0 million in net proceeds from the sale of securities pursuant to the Sales Agreement.”
The company is actively using its ATM facility to fund operations, which puts continuous downward pressure on the stock price and dilutes existing shareholders.
Contra-Expense Accounting Gimmick
“The premium was recorded to accrued expenses and other long-term liabilities... and will be recognized as a credit to research and development expense over the collaboration term.”
A $2.5 million premium paid by AMD for shares is being used to artificially reduce reported R&D expenses rather than being treated as purely an equity transaction, masking the true cost of research.
Unsustainable Burn Rate vs. Cash Position
“Net cash used in operating activities [-26307]... Cash, cash equivalents, and restricted cash - End of period [9689]”
With a quarterly operating burn of over $26M and only $8.6M in pure cash (bolstered by $117M in marketable securities), the company has approximately 4-5 quarters of runway before requiring a major capital raise.
Intrinsic value should be heavily discounted due to the certainty of future dilution; the company's reliance on ATM sales suggests they are price-takers in the equity market.
Accounts Payable ballooned from $2.7M to $8.8M (a 220% increase) in just three months, suggesting the company is stretching payables to manage its dwindling cash position.